Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Novavax Inc (NVAX) vs Viking Holdings Ltd Ordinary Shares (VIK) Price & Performance

Novavax IncTrade
Viking Holdings Ltd Ordinary SharesTrade

Price performance (Past 24H)

Key statistics

Novavax Inc vs Viking Holdings Ltd Ordinary Shares — how do they compare? Novavax Inc trades at $11 (market cap $1.85B), while Viking Holdings Ltd Ordinary Shares trades at $81.62 (market cap $36.29B). The key difference: Viking Holdings Ltd Ordinary Shares is far larger — about 19.6× Novavax Inc's market cap, and Novavax Inc is trading nearer its 52-week high, Viking Holdings Ltd Ordinary Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and Viking Holdings Ltd Ordinary Shares for 0 Days on average.

NVAXVIK
Market Cap
$1.85B$36.29B
Volume
8,362,5622,522,956
Sector
HealthConsumer Cyclical
52-Week High
$12.56$108.26
52-Week Low
$6.22$57.08
Typical Hold Time
59 Days0 Days
Enterprise Value
$1.43B$38.67B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Novavax Inc

Novavax (NVAX) trades at $11.01, down 2.74% on the day, with a mixed technical picture showing bullish moving averages but neutral oscillators. The company reported strong revenue of $1.12B in 2025 with a net income of $440.30M, though 2026 projections show a return to losses. Recent news highlights the company's pivot to a partnership-driven model using its Matrix-M adjuvant technology, with regulatory approvals for its updated COVID-19 vaccine in major markets.

Investment outlook remains speculative with analyst consensus heavily favoring Buy ratings (73.92%) but fundamental risks persist including negative cash flow trends and high debt levels. The stock offers potential upside from partnership expansions but faces significant execution and competitive risks in the biopharma sector.

Viking Holdings Ltd Ordinary Shares

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

NVAX
59% Buy41% Sell
Avg holding period · 59 Days
VIK
100% Buy0% Sell
Avg holding period · 0 Days

Top news

Latest headlines on both assets

About Novavax Inc

Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.

Read more on NVAX →

About Viking Holdings Ltd Ordinary Shares

Viking operates river, ocean, and expedition cruises. Its itineraries focus on destination-based travel across Europe, the Americas, and other regions.

Read more on VIK →